Our AVI-PDX™ and AVI-cellDX™ models

Oncofactory operates a unique technological platform exploiting an innovative patient-derived xenograft (PDX) animal model, the avian embryo. Miniature replicas of tumors from patient samples (AVI-PDX™) or from cell lines (AVI-cellDX™) are created in a series of embryos, which can receive therapeutic treatments.

Our technology allows modeling the heterogeneity of patient tumors, statistical analysis of treatment efficacies, and a range of molecular analyses for biomarker and therapeutic target discovery.

The AVI-PDX™ model of Oncofactory holds the unique advantage of allowing the creation of tumors and the delivery of therapeutic compounds (small molecule, targeted therapy, immunotherapy) in only a few days. Moreover, the tumorigenesis is targeted onto tissues which are homologous to those in which primary tumors emerge in the patient or in known sites of metastasis. Tumor replicas are imaged in 3D in the entire organism by using high resolution confocal microscopy. A range of molecular analyses can also be conducted on tumor replicas, host tissues and fluids, to achieve a molecular profiling characterizing the sensitivity and resistance to treatments.

  Our AVI-Tumoral models

Our most recent R&D achievement:
iAVI-models to evaluate immunotherapy
in mono and combi-therapies

AVI-cellDX™

AVI-cellDX™

CELL LINES

AVI-PDX™

AVI-PDX™

PATIENT BIOPSIES

iAVI-cellDX™

iAVI-cellDX™

CELL LINES

iAVI-cellDX™

iAVI-PDX™

PATIENT BIOPSIES

HUMANIZED WITH IMMUNE CELLS

Find out our offers :

This technology is protected by 2 patents :

1.EP 3 167 048 B1 • 2.WO 2017/103025

 Graft of patient sample

 into the embryo

picto Tissues and organs are already
prefigured in the embryo

picto Due to high degree of inter-specie
conservation, human cells can read the
signals from the avian microenvironment

KEY ADVANTAGES

picto Tumorigenesis is targeted into selected territories corresponding to patient primary tumor sites or to known metastatic sites.

picto Cancer cells exploit tissue specific signals to proliferate and to establish metastases.

picto How and why does our model work ?

Classically, patient-derived xenografts (PDX) are achieved under the skin of adult immune-deprived mice and take weeks to months to give rise to tumors. The dermis environment strongly differs from that of tissues in which tumors form in the patients and is poor in signals important for tumors to develop. In contrast, the embryonal tissues are rich in signals, different from one tissue to the other one, which ensure their building. The same signals will mediate tissue renewal at adulthood.

Thus, tumoral cells can recognize these signals in the embryo and exploit them to proliferate and disseminate. By selecting the tissue in which tumors will form, we confront tumoral cells to an environment which evokes that of their site of origin in the patient. This makes it our model powerful to generate tumors in an optimal range of time. Delloye-Bourgeois et al., Cancer Cell, 2017

picto Advantages on existing PDX models

Avi-PDX™ model

FAST

picto Tumoral masses in 48h, Metastasis in 2 to 7 days

STATISTICAL ANALYSIS

One patient/ series of standard replicas

REPRODUCIBLE ORTHOTOPIC TUMORS

Tumorigenesis targeted in tissues homologous to those of the patients 100% tumor intake from patient samples

EASY ETHIC PROCEDURE, HIGH FLEXIBITY

2013 86/609/EEC rule, no need for protocol approval

EASY SAMPLE ENGINEERING

Reduced biological sample Biobanking

Mouse PDX model

SLOW

picto Tumors in several weeks to months

Qualitative analysis

One patient/ a few mice

Versatile heterotopic tumors

Highly variable tumor intake Irrelevant tissue environment (subcutaneous site)

Complex ethic procedure, Low flexibility

Protocol approval by Ethic committee

Complex sample engineering

Substantial amount of fresh patient sample

vs

CAM assay in the egg

Graft of tumoral cell lines on chick
chorioallantoid membrane (CAM)

picto Adapted to cell lines

ex vivo set-up :

Tumors outside the organism (grafting on the external chorioallantoid membrane)

Process in 2 to several weeks

Variability of intake and Heterogeneity of tumor growth

Therapeutic compounds generally infused on top of the tumoral cells

picto Process of studies by Oncofactory

Each project is managed by a unique scientific contact, in 3 steps:
• Exploratory meetings to precisely define the objectives and the specific requirements
(timetable, budget, scientific and technological issues)
• Customized studies with go/no-go decisions ensuring cost optimization and maximal
flexibility
• Reporting with validated data, statistical analysis and images of each step of imaging
and quantification processes

picto Our study process also guarantees:

exemples Confidentiality of client information
exemples Flexibility and reactivity
exemples Respect of deadlines
exemples Validated and reproducible standards, in-house experimental models and assays
exemples Total traceability and transparency of the procedures and data

Patient cancer sample supply

 

picto

 

Oncofactory established partnerships with key hospitals and clinics specialized in cancer treatment.

Scientific equipments

 

picto

 

Oncofactory is equipped with state-of-the-art materials. Moreover, our accomodation in the Neuromyogene Institute allows access to various equipments.

Quality managment :

 

picto

 

Studies are conducted following requirements based on the OECD Good Laboratoty Practices, reference ENV/MC/CHEM(98) 17 adopted by Council on 26th November, 1997.

Ethics :

 

picto

 

Light ethic procedure with a high flexibility: 2013 86/609/EEC rule, No need for protocol approaval.